ImmunityBio, Inc. (IBRX) Insider Trading Activity

NASDAQ$5.945
Market Cap
$5.86B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
623 of 888
Rank in Industry
359 of 508

IBRX Insider Trading Activity

IBRX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$1,531,947
3
100

Related Transactions

Selecky Christobeldirector
0
$0
2
$437,650
$-437,650
Simon Barry J.director
0
$0
1
$1.09M
$-1.09M

About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Insider Activity of ImmunityBio, Inc.

Over the last 12 months, insiders at ImmunityBio, Inc. have bought $0 and sold $1.53M worth of ImmunityBio, Inc. stock.

On average, over the past 5 years, insiders at ImmunityBio, Inc. have bought $173,894 and sold $2.13M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 71,915 shares for transaction amount of $198,023 was made by BLASZYK MICHAEL D (director) on 2023‑06‑05.

List of Insider Buy and Sell Transactions, ImmunityBio, Inc.

2026-01-20SaleSimon Barry J.director
151,967
0.0171%
$7.20
$1.09M
-13.75%
2026-01-20SaleSelecky Christobeldirector
25,000
0.0029%
$7.51
$187,650
-13.75%
2026-01-16SaleSelecky Christobeldirector
50,000
0.0046%
$5.00
$250,000
+14.13%
2023-06-05PurchaseBLASZYK MICHAEL Ddirector
71,915
0.0166%
$2.75
$198,023
+30.82%
2023-06-02PurchaseBrennan John Owendirector
25,000
0.006%
$2.83
$70,700
+31.77%
2023-06-02PurchaseBrennan John Owendirector
15,000
0.0035%
$2.78
$41,700
+31.77%
2023-06-01PurchaseClark Wesleydirector
7,000
0.0016%
$2.91
$20,370
+24.15%
2021-10-08PurchaseAdcock RichardCEO & President
1,930
0.0005%
$8.81
$16,995
-38.25%
2021-08-23SaleCohen Cheryldirector
14,801
0.0035%
$10.12
$149,795
-45.86%
2021-08-20SaleCohen Cheryldirector
9,976
0.0025%
$10.00
$99,808
-41.00%
2021-08-18SaleCohen Cheryldirector
2,133
0.0006%
$10.03
$21,389
-36.74%
2021-08-17SaleCohen Cheryldirector
43,398
0.0112%
$10.12
$439,361
-41.04%
2021-05-25SaleSimon Barry J.director
88,787
0.0237%
$16.18
$1.44M
-54.64%
2021-05-24SaleSimon Barry J.director
21,223
0.0056%
$16.02
$340,071
-54.46%
2021-05-21SaleSimon Barry J.director
14,990
0.0039%
$16.09
$241,164
-53.43%
2021-02-05SaleSimon Barry J.See remarks
22,100
0.0056%
$23.09
$510,267
-52.76%
2021-02-02SaleSimon Barry J.See remarks
82,070
0.0212%
$20.65
$1.69M
-46.10%
2021-01-28SaleSimon Barry J.See remarks
11,304
0.0033%
$20.53
$232,121
-39.34%
2021-01-27SaleSimon Barry J.See remarks
36,626
0.01%
$20.61
$754,946
-42.76%
2021-01-12SaleNelson SonjaChief Financial Officer
16,364
0.004%
$15.00
$245,460
-26.52%
Total: 83
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Simon Barry J.director
3091604
0.3139%
$18.38M021
Selecky Christobeldirector
0
0%
$002
SOON-SHIONG PATRICKChairman and CEO
23750750
2.4113%
$141.2M20
<0.0001%
Thomas John Cdirector
207477
0.0211%
$1.23M014
Cohen Cheryldirector
200617
0.0204%
$1.19M05
DRISCOLL FREDERICK Wdirector
109235
0.0111%
$649,402.0801
BLASZYK MICHAEL Ddirector
71915
0.0073%
$427,534.6810
+30.82%
Nelson SonjaChief Financial Officer
15410
0.0016%
$91,612.4502
Brennan John Owendirector
15000
0.0015%
$89,175.0020
+31.77%
Clark Wesleydirector
8000
0.0008%
$47,560.0010
+24.15%
Wilson AngelaChief Financial Officer
3265
0.0003%
$19,410.4310
<0.0001%
Adcock RichardCEO & President
1930
0.0002%
$11,473.8510
<0.0001%
GORLIN STEVEdirector
0
0%
$0030
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$224,382,625
44
27.62%
$5.33B
$477,065,869
34
82.05%
$5.24B
$1,801,511
23
18.58%
$8.94B
$103,944,213
17
5.95%
$6.54B
$11,859,102
17
18.62%
$8.1B
$1,279,017
16
51.12%
$9.14B
$74,605,681
14
47.06%
$5.09B
$57,686,748
13
21.11%
$5.58B
$75,296,863
13
33.79%
$6.5B
$9,976,473
12
29.52%
$6.71B
$2,477,801
11
4.98%
$5.48B
$3,073,199
10
16.77%
$4.84B
$11,898,979
10
54.58%
$8.02B
$35,908,794
10
126.31%
$5.09B
$25,064,843
9
12.75%
$4.69B
$20,499,451
9
71.54%
$5.55B
ImmunityBio, Inc.
(IBRX)
$55,713,031
8
-0.36%
$5.86B
$105,414,951
5
10.07%
$7.33B
$41,376,000
4
-12.07%
$7.68B

IBRX Institutional Investors: Active Positions

Increased Positions147+63.36%38M+29.31%
Decreased Positions84-36.21%20M-15.31%
New Positions52New11MNew
Sold Out Positions20Sold Out8MSold Out
Total Postitions295+27.16%150M+14%

IBRX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$55,864.002.81%27.66M+6M+26.76%2025-09-30
Blackrock, Inc.$40,018.002.01%19.81M+2M+11.5%2025-09-30
Jane Street Group, Llc$25,928.001.3%12.84M+5M+66.3%2025-09-30
State Street Corp$22,858.001.15%11.32M+4M+48.59%2025-09-30
Geode Capital Management, Llc$13,918.000.7%6.89M+1M+19.26%2025-09-30
Heights Capital Management, Inc$13,263.000.67%6.57M+7MNew2025-09-30
Woodline Partners Lp$10,701.000.54%5.3M+2M+53.74%2025-09-30
Morgan Stanley$6,815.000.34%3.37M+401,301+13.5%2025-09-30
Alphacore Capital Llc$6,037.000.3%2.99M+13,666+0.46%2025-09-30
Susquehanna International Group, Llp$5,338.000.27%2.64M+790,746+42.7%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.